Randomized Phase II Trial of Erlotinib Versus Temozolomide or Carmustine in Recurrent Glioblastoma: EORTC Brain Tumor Group Study 26034

PURPOSE: Approximately 50% of glioblastomas (GBMs) are characterized by overexpression of the epidermal growth factor receptor (EGFR) and EGFR gene amplification. In approximately 25% of instances, constitutively activated EGFR mutants are present. These observations make EGFR-inhibiting drugs a log...

Full description

Saved in:
Bibliographic Details
Main Authors: van den Bent, Martin J., Brandes, Alba A., Rampling, Roy, Kouwenhoven, Mathilde C.M., Kros, Johan M., Carpentier, Antoine F., Clement, Paul M., Frenay, Marc, Campone, Mario, Baurain, Jean-Francois, Armand, Jean-Paul, Taphoorn, Martin J.B., Tosoni, Alicia, Kletzl, Heidemarie, Klughammer, Barbara, Lacombe, Denis, Gorlia, Thierry
Format: Artigo
Language:Inglês
Published: American Society of Clinical Oncology 2009
Subjects:
Original Reports
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC2667826/
https://ncbi.nlm.nih.gov/pubmed/19204207
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2008.17.5984
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items